VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

ESH CML 2022 | The use of BCR:ABL1 digital PCR to identify patients with CML suitable for early TKI discontinuation

Camille Kockerols, MD, Albert Schweitzer Hospital, Dordrecht, Netherlands, talks on the use of BCR:ABL1 digital PCR as a predictor of treatment-free remission (TFR) independent of treatment duration in patients with chronic myeloid leukemia (CML) that can be used to identify patients who qualify for early tyrosine kinase inhibitor (TKI) discontinuation. This interview took place at the 24th Annual John Goldman Conference on Chronic Myeloid Leukemia (ESH CML) held in Mandelieu-La Napoule, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter